Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Shuts U.S./EU Phase III Diabetes Trial But Resumes Asia Development For Differentiated Markets

This article was originally published in The Pink Sheet Daily

Executive Summary

Astellas’ multi-track R&D approach leaves door open for a Western partner interested in a Phase III SGLT2 inhibitor, but the Japanese pharma’s main interest is finding ipragliflozin’s niche in Asia.

You may also be interested in...



Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission

Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.

Astellas Outlicenses Products To California Startup, Considers Expanding Model To More Of Its Portfolio

TOKYO - Astellas Pharma Inc. is trying out a new model, out-licensing three compounds to a startup created specifically to support the development of the products while Astellas retains options to buy back the products. The Japanese pharma is reducing costs for non-priority therapeutic targets, and if successful, may repeat the model for other compounds in its pipeline

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?

Topics

Related Companies

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel